From GlobeNewswire: 2024-04-10 07:30:00

Theratechnologies reported Q1 2024 revenue of $16.2 million, marking the third consecutive quarter of near-flat-to-positive Adjusted EBITDA. The company reiterated its FY2024 revenue guidance of $87-$90 million and Adjusted EBITDA of $13-$15 million. The Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer is progressing with enrollment at a higher dose level. New Board of Directors members were appointed, and promising data was presented at the American Association for Cancer Research Annual Meeting 2024.

In Q1 2024, Theratechnologies reported a decrease in revenue to $16.2 million compared to $19.9 million in the same period last year. EGRIFTA SV® sales decreased by 24.6% to $9.6 million, while Trogarzo® sales decreased by 7.4% to $6.7 million. This decline was mainly attributed to lower unit sales due to inventory loading in the prior year and larger government rebates and returns in Q1 2024. Cost of sales for the quarter was $5.3 million.



Read more at GlobeNewswire:: Theratechnologies Reports Financial Results and Provides